

January 5, 2015



Qualcomm announces strategic collaboration with Novartis to optimize global clinical trials

--Novartis selects Qualcomm Life and its 2net technology to digitize its clinical trials--

SAN DIEGO, Jan. 5, 2015 /PRNewswire/ -- Qualcomm Incorporated (NASDAQ: QCOM) today announced that its subsidiary, [Qualcomm Life, Inc.](#), has been selected by Novartis, a global pharmaceutical leader, as a global digital health collaborator for its Trials of The Future program. Qualcomm Life's 2net™ Platform will serve as a global connectivity platform for collecting and aggregating medical device data during clinical trials to improve the convenience and speed of capturing study participant data and test results to ultimately gain more trial efficiencies and connected experiences for participants.

The Trials of The Future program is designed to leverage health care technology to improve the experience of clinical trial participants and patients using Novartis products, and provide connectivity with future products marketed by Novartis. Novartis will combine the 2net Platform, 2net Hub and 2net Mobile technologies with designated medical devices to automate the collection of vital patient data at patient's homes during clinical trials.

"Novartis is a pioneer in putting technology to use in advancing pharmaceutical innovation," said Rick Valencia, senior vice president and general manager, Qualcomm Life. "Standardizing on the tech-agnostic 2net Platform and accessing the robust ecosystem of integrated medical devices will provide them a great range of flexibility and scalability, ultimately accelerating their efforts to design more efficient, cost-effective clinical trials."

Novartis is using the 2net Platform in a recently-launched clinical study, evaluating the use of mobile devices with chronic lung disease patients. The study, which is observational in nature and does not involve any Novartis pharmaceutical product, leverages 2net Mobile-enabled smartphones and 2net Hubs to seamlessly collect and aggregate biometric data from medical devices and transmits this data to the cloud-based 2net Platform, which securely sends the data to the study coordinator.

Qualcomm Life to Have Significant Presence at CES 2015

Qualcomm Life will showcase chronic care and transitional care management demos at booth #8525 in Central Hall, Las Vegas Convention Center. James Mault, MD, F.A.C.S., vice president and chief medical officer, Qualcomm Life, will participate in a fireside chat on what is new in Quantified Self from 3:30-4:30 p.m. in the Las Vegas Convention Center Room, N621 on Monday, January 5. Rick Valencia, senior vice president and general manager, Qualcomm Life, will participate in a fireside chat with Corinne Savill, head of business development and licensing, Novartis, titled "Pharma goes Techy and Consumers Score" from 9:40-10:04 a.m. at the Digital Health Summit at the Venetian level 2 Bellini Room 2004 on Thursday, January 8.

About Qualcomm Incorporated

Qualcomm Incorporated (NASDAQ: QCOM) is a world leader in 3G, 4G and next-generation wireless technologies. Qualcomm Incorporated includes Qualcomm's licensing business, QTL, and the vast majority of its patent portfolio. Qualcomm Technologies, Inc., a wholly-owned subsidiary of Qualcomm Incorporated, operates, along with its subsidiaries, substantially all of Qualcomm's engineering, research and development functions, and substantially all of its products and services businesses, including its semiconductor business, QCT. For more than 25 years, Qualcomm ideas and inventions have driven the evolution of digital communications, linking people everywhere more closely to information, entertainment and each other. For more information, visit Qualcomm's [website](#), [OnQ blog](#), [Twitter](#) and [Facebook](#) pages.

Qualcomm and 2net are trademarks of QUALCOMM Incorporated, registered in the United States and other countries. Other product and brand names may be trademarks or registered trademarks of their respective owners.

Qualcomm Contacts:
Emily Kilpatrick, Corporate Communications
Phone: 1-858-845-5959
Email: corpcomm@qualcomm.com

Jamie Eisinger, Qualcomm Life, Inc.
Phone: 1-858-845-1033
Email: jeisinge@qti.qualcomm.com

Warren Kneeshaw, Investor Relations
Phone: 1-858-658-4813
Email: ir@qualcomm.com

To view the original version on PR Newswire, visit <http://www.prnewswire.com/news-releases/qualcomm-announces-strategic-collaboration-with-novartis-to-optimize-global-clinical-trials-300015804.html>

SOURCE Qualcomm Incorporated